In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis;Actividad in vitro de linezolid, moxifloxacino, levofloxacino, clindamicina y rifampicina, solos o en combinación, frente a Staphylococcus aureus y Staphylococcus epidermidis

Revista Espanola de Quimioterapia

Volumn 18, Issue 2, 2005, Pages 168-172

  Soriano, Alex ^a   Jurado, A ^a   Marco, F ^a   Almela, M ^a   Ortega, M ^a   Mensa, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotic combinations; Fluoroquinolones; Oxazolidinones; Staphylococcus aureus; Staphylococcus epidermidis

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BLOOD CULTURE; DRUG ACTIVITY; IN VITRO STUDY; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLINDAMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; OXAZOLIDINONES; QUINOLINES; RIFAMPIN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 23044510777     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Zimmerli, W., Widmer, A.F., Blatter, M., Frei, R., Ochsner, P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-1541.
2. Stein, A., Bataille, J.F., Drancourt, M. y cols. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086-3091.
3. Segreti, J., Nelson, J.A., Trenholme, G.M. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis 1998; 27: 711-713.
4. Jones, M.E., Visser, M.R., Klootwijk, M., Heisig, P., Verhoef, J., Schmitz, F.J. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999; 43: 421-423.
5. Von Eiff, C., Peters, G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999; 43: 569-573.
6. Gander, S., Hayward, K., Finch, R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother 2002; 49: 301-308.
7. Hackbarth, C.J., Chambers, H.F., Sande, M.A. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29: 611-613.
8. Grohs, P., Kitzis, M.D., Gutmann, L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 418-420.
9. Jacqueline, C., Caillon, J., Le, M.V. y cols. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-864.
10. Mulazimoglu, L., Drenning, S.D., Yu, V.L. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40: 2428-2430.
11. Sweeney, M.T., Zurenko, G.E. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother 2003; 47: 1902-1906.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; approved standard. NCCLS, Wayne, PA, USA 2000; Fifth ed., M7-A5.
13. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Document M26-A. NCCLS, Wayne, Pa 1999.
14. Fass, R.J., Helsel, V.L. In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs. Antimicrob Agents Chemother 1987; 31: 1457-1460.
15. Dworkin, R.J., Lee, B.L., Sande, M.A., Chambers, H.F. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989; ii: 1071-1073.
16. Costerton, J.W., Lewandowski, Z., Caldwell, D.E., Korber, D.R., Lappin-Scott, H.M. Microbial biofilms. Ann Rev Microbiol 1995; 49: 711-745.
17. Stewart, P.S., Costerton, J.W. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-138.
18. Bahl, D., Miller, D.A., Leviton, I. y cols. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 1293-1297.
19. Widmer, A.F., Frei, R., Rajacic, Z., Zimmerli, W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990; 162: 96-102.
20. Andes, D., van Ogtrop, M.L., Peng, J., Craig, W.A. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46: 3484-3489.